Novartis plots to retain hives patients with monoclonal antibody that outshines Xolair

After the loss of patent protection on its Roche-partnered hives therapy Xolair, Novartis $NVS has found its experimental monoclonal antibody ligelizumab surpassed Xolair in a mid-stage hives trial, allowing the company to shepherd it along to Phase III trials.